Sprout Group Announces $12 Million Financing In Sopherion Therapeutics, Inc.
10/19/2005 5:10:55 PM
Sprout Group announced today that the Company has invested $12 million as part of a $47 million Series B Financing in Sopherion Therapeutics, Inc., a biopharmaceutical company focusing on the development and commercialization of anti-cancer therapies. In addition to Sprout Group's financing and a lead investment by TL Ventures, the remainder of the funding came from ProQuest, Canaan Partners, HealthCap, NewSpring Ventures, L.P., Commerce Health Ventures, and Seaflower Ventures.
comments powered by